Gastrointestinal toxicity and clostridium difficile diarrhea in patients treated with paclitaxel-containing chemotherapy regimens

Gynecologic Oncology

Volumn 71, Issue 1, 1998, Pages 104-107

  Husain, Amreen ^a   Aptaker, Lisa ^b   Spriggs, David R ^a   Barakat, Richard R ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Lincoln Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLOSTRIDIUM DIFFICILE; COLON FLORA; DEHYDRATION; DIARRHEA; DRUG EFFECT; FEMALE; GASTROINTESTINAL TOXICITY; GYNECOLOGIC CANCER; HUMAN; MAJOR CLINICAL STUDY; NAUSEA; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VOMITING;

EID: 0032191385     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1998.5158     Document Type: Article

References (10)

1. Kelly C P, Pothoulakis C, Lamont J T. Clostridium difficile. N Engl J Med. 130:1994;257-262.
2. Bartlett J G. Clostridium difficile: Clin Infect Dis. 18:1994;S265-S272.
3. Hirschhorn L R, Trnka Y, Onderdonk A, Lee M T, Platt R. Epidemiology of community-acquiredClostridium difficile. J Infect Dis. 69:1994;127-133.
4. Job M L, Jacobs N F Jr. Drug-inducedClostridium difficile. Drug Saf. 17:1997;37-46.
5. Kamthan A G, Bruckner H W, Hirschman S Z, Agus S. Clostridium difficile. Arch Intern Med. 152:1992;1715-1717.
6. Emoto M, Kawarabayashi T, Hachisuga T, Eguchi F, Shirakawa K. Clostridium difficile. Gynecol Oncol. 61:1996;369-372.
7. Anand A, Glatt A E. Clostridium difficile. Clin Infect Dis. 17:1993;109-113.
8. Bodey G, Abi-Said D, Rolston K, Raad I, Whimbey E. Imipenem or cefoperazone-sulbactam combined with vancomycin for therapy of presumed or proven infection in neutropenic cancer patients. Eur J Clin Microbiol Infect Dis. 15:1996;625-634.
9. Cirisano F D, Greenspoon J S, Stenson R, Farias-Eisner R, Karlan B Y, Lagasse L D. The etiology and management of diarrhea in the gynecologic oncology patient. Gynecol Oncol. 50:1993;45-48.
10. Aghajanian C, Fennelly D, Shapiro F, Waltzman R, Almadrones L, O'Flaherty C, O'Conner K, Venkatraman E, Barakat R, Curtin J, Brown C, Reich L, Wuest D, Norton L, Hoskins W, Spriggs D R. Phase II study of "dose dense" high-dose chemotherapy treatment with peripheral blood progenitor cell support as primary treatment for patients with advanced ovarian cancer. J Clin Oncol. 16:1998;1852-1860.